AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7040955
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment and infusion of 5% glucose (Control)
Trial: 22258156
Drug: bihemispheric tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy during the first 5-day period
Trial: 22258156
Drug: bihemispheric tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy during the second 5-day period
Trial: 22258156
Drug: bihemispheric tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy over two periods
Trial: 17237312
Drug: Lean red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean red meat intake (approximately 200 g/d)
Trial: 10368879
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=6) - no drug treatment, only exercise training
Trial: 10368879
Drug: Pretreatment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment group (n=6) - previously treated with fluvastatin 20 mg/day
Trial: 10368879
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (n=6) - received fluvastatin 20 mg/day during training
Trial: 9050100
Drug: 4% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lignocaine solution
Trial: 1908385
Drug: Buccal nitroglycerin
RxNorm normalized name: nitroglycerin Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal nitroglycerin
Trial: 7046434
Drug: Combined hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hydrochlorothiazide (25 to 50 mg twice a day) and furosemide (increased doses of 320 to 480 mg/day)
Trial: 7046434
Drug: Furosemide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (160 to 240 mg/day)
Trial: 18456649
Drug: Ivermectin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (24 mg)
Trial: 8889399
Drug: Enhanced Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Intervention (EI) - SI plus additional educational sessions stressing responsible drug use, including active referral in some cities.
Trial: 8889399
Drug: Treatment (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (both SI and EI) compared to other interventions.
Trial: 1686817
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLX) treatment
Trial: 31092172
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells (MSCs) injection
Trial: 31092172
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical therapy (anti-TNF agents) with setons and additional surgical techniques
Trial: 29223955
Drug: Perioperative atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative atorvastatin treatment
Trial: 29223955
Drug: Increasing long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing long-term statin dose
Trial: 17724088
Drug: Ciprofloxacin PR
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin PR (500 mg)
Trial: 17724088
Drug: Warfarin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (7.5 mg)
Trial: 17724088
Drug: Warfarin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (7.5 mg) + Ciprofloxacin PR (500 mg)
Trial: 15339496
Drug: Kuhuang Injection,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuhuang Injection, Shenmai Injection, Huangqi Liquid (treatment group)
Trial: 15339496
Drug: Ribarvirin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribarvirin and Ganlixin Injection (control group)
Trial: 8025391
Drug: Cow's milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk-based formula with 4 mg of iron/l
Trial: 8025391
Drug: Cow's milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk-based formula with 7 mg of iron/l
Trial: 8025391
Drug: Cow's milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk-based formula with selenium (10 micrograms/l)
Trial: 27871275
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200 mg once daily)
Trial: 10999810
Drug: DHEA 25
RxNorm normalized name: GNP DHEA 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 25 mg
Trial: 9118514
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg UID
Trial: 9118514
Drug: Treatment-induced changes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced changes in average daytime and nighttime BPs
Trial: 8419392
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of cefotiam, given twelve hours apart
Trial: 3025151
Drug: Various formulations
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various formulations of acyclovir
Trial: 25867608
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (20 mg of esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily for 10 days)
Trial: 25867608
Drug: Hybrid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid therapy (5-day dual therapy of 20 mg of esomeprazole and 1 g of amoxicillin, twice daily followed by 5-day quadruple therapy of 20 mg of esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Trial: 20854305
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium solution with DMSO
Trial: 20854305
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium gel
Trial: 19242406
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg memantine (in rats)
Trial: 19242406
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg memantine (in rats)
Trial: 14980936
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation with V(T) = 12 or 15 mL/kg ideal body weight, zero end‐expiratory pressure
Trial: 14980936
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation with V(T) = 6 mL/kg ideal body weight, positive end‐expiratory pressure of 10 cm H(2)O
Trial: 11446564
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily (n = 59)
Trial: 9543191
Drug: Root-resective therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root-resective therapy with osseous recontouring and apically positioned flaps
Trial: 3273486
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 micrograms in 5 ml sterile normal saline
Trial: 7788195
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of saline
Trial: 26171380
Drug: Medicine only
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine only
Trial: 27798546
Drug: Corticosteroids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids at the start of fluid therapy (group C)
Trial: 27798546
Drug: Corticosteroids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids at step 3 of treatment (group A)
Trial: 27798546
Drug: Corticosteroids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids at step 3 of treatment with adrenal stimulation test (group B)
Trial: 25709044
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for antenatal depression and anxiety
Trial: 24300755
Drug: Clarithromycin 25
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 25 mg daily for 6 months
Trial: 24300755
Drug: Clarithromycin 25
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 25 mg daily for 3 months
Trial: 24300755
Drug: Basal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal therapy with mometasone furoate 400 mcg daily
Trial: 21972623
Drug: Indomethachin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethachin (25 mg orally, three times per day for 5 days)
Trial: 11376303
Drug: Epoprostenol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol therapy (n = 201)
Trial: 9834590
Drug: Thiamylal 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 5 mg.kg‐1 with vecuronium 0.1 mg.kg‐1
Trial: 9834590
Drug: Thiamylal 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 3 mg.kg‐1 with additional thiamylal 4 mg.kg‐1 before intubation and vecuronium 0.1 mg.kg‐1
Trial: 9834590
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg.kg‐1 with vecuronium 0.1 mg.kg‐1
Trial: 7926305
Drug: Beta-hydroxybutyrate (BOHB)
RxNorm normalized name: L-alpha-amino-beta-hydroxybutyric acid
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-hydroxybutyrate (BOHB) infusion
Trial: 2687006
Drug: Oxindanac 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxindanac 300 mg b.d.
Trial: 2687006
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg b.d. with oxindanac
Trial: 2687006
Drug: Frusemide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 40 mg b.d. with placebo
Trial: 20671100
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (standard of care)
Trial: 28902073
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (among hrHPV+ women)
Trial: 23483214
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintaining usual daily activity
Trial: 21600129
Drug: Target Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Controlled Infusion (TCI) of propofol at an initial plasma concentration of 2.0 µg/ml, titrated upwards by 0.5 µg/ml steps until loss of consciousness
Trial: 21600129
Drug: Manual Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Controlled Infusion (MCI) of propofol at 200 ml/h
Trial: 21600129
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received an infusion of remifentanil
Trial: 16420540
Drug: Glycerol cream
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycerol cream
Trial: 16420540
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil cream
Trial: 16420540
Drug: Bisabolol cream
DrugBank: Levomenol (DB13153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bisabolol cream
Trial: 16420540
Drug: Carbomer cream
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbomer cream
Trial: 16420540
Drug: Basic cream
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic cream
Trial: 16420540
Drug: IPP cream
RxNorm normalized name: IPPD
DrugBank: 4-(Isopropylamino)diphenylamine (DB14195)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPP cream
Trial: 12904840
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g) and vitamin D (800 units of cholecalciferol) only (group 1: n=35)
Trial: 12904840
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D and nutritional supplement drink providing 300 Kcal, 12 g protein, 11.6 g fat, and 36.8 g carbohydrate per carton (group 2: n=36)
Trial: 12904840
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D and nutritional supplement drink (group 2)
Trial: 11309029
Drug: Bexarotene capsules
RxNorm normalized name: Bexarotene Capsules
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene capsules (300 mg/m2 per day)
Trial: 11309029
Drug: Bexarotene gel
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene gel
Trial: 2925967
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment (Control)
Trial: 10442506
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg daily (doubled to 7.1 mg daily if diastolic blood pressure > 90 mmHg)
Trial: 10442506
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg daily (doubled dosage if diastolic blood pressure > 90 mmHg)
Trial: 7503838
Drug: Ibuprofen (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (with at least 70% compliance)
Trial: 2217684
Drug: Amoxycillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (3 g) twice daily for 32 weeks
Trial: 2217684
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 32 weeks
Trial: 21513688
Drug: Very-low-dose naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-dose naltrexone (VLNTX) 0.125 or 0.250 mg/day
Trial: 17679044
Drug: A/B antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/B antihypertensive agents
Trial: 17679044
Drug: C/D antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C/D antihypertensive agents
Trial: 15385805
Drug: ISIS 2302
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 2302 (0.05, 0.5, 1.0, or 2.0 mg/kg)
Trial: 11351767
Drug: Combined DTP-HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DTP-HBV vaccine
Trial: 11351767
Drug: Separate DTP
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate DTP and HBV vaccines
Trial: 9562774
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of a questionnaire on the health of the elderly and introduction of the concept of activities of daily living
Trial: 6315038
Drug: DAMME (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAMME (0.25 mg)
Trial: 30877186
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg PF‐06372865
Trial: 30877186
Drug: 52.5 mg
RxNorm normalized name: carbidopa 52.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52.5 mg PF‐06372865
Trial: 24517906
Drug: Saline (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.2 mL)
Trial: 22237063
Drug: Leptin (replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin (replacement doses)
Trial: 22237063
Drug: Placebo (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice-daily injections)
Trial: 12527321
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline injections (0.1 ml of 0.9%, 2%, 4%, and 6% and 0.2 ml of 2% and 4%)
Trial: 12527321
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 4% saline
Trial: 12527321
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline injections)
Trial: 8195851
Drug: Brodimoprim 200
RxNorm normalized name: brodimoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim 200 mg tablets (2 tablets on the first day, 1 tablet on following days)
Trial: 8195851
Drug: Josamycin 500
RxNorm normalized name: josamycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin 500 mg tablets (3 tablets/day)
Trial: 3515951
Drug: Single 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 gm dose of cefotetan
Trial: 3515951
Drug: Multidose cefoxitin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose cefoxitin (2 gm every 4 hours for three doses)
Trial: 22103390
Drug: Palpation-guided arthrocentesis
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided arthrocentesis with a conventional 20-mL syringe
Trial: 22103390
Drug: US-guided arthrocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided arthrocentesis with a 25-mL reciprocating procedure device (RPD) mechanical aspirating syringe
Trial: 22103390
Drug: US-guided arthrocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided arthrocentesis with a 60-mL automatic aspirating syringe
Trial: 19067474
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 400 microg administered via a dry powder inhaler once daily in the evening (MF‐DPI 400 microg qd pm)
Trial: 19067474
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered between 6 pm and 8 pm for 14 days
Trial: 16045025
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine (3.0 mL, 15 mg)
Trial: 16045025
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (3.0 mL, 15 mg)
Trial: 11896484
Drug: SSRIs (Selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (Selective Serotonin Reuptake Inhibitors)
Trial: 8123997
Drug: bFGF (bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF (bovine fibroblast growth factor) administered intramuscularly at dosages of 0.4 or 0.28 microgram kg-1, once or twice a month, over 7-12 months
Trial: 8123997
Drug: bFGF (bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bFGF (bovine fibroblast growth factor) administered intramuscularly
Trial: 2442538
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat (ET) 5 mg
Trial: 2442538
Drug: Oral enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enalapril (E) 10 mg
Trial: 2442538
Drug: Intravenous enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enalapril (E) 5 mg
Trial: 2442538
Drug: Oral lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral lisinopril (LI) 10 mg
Trial: 2442538
Drug: Intravenous lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lisinopril (LI) 5 mg
Trial: 29526707
Drug: Self-administered DMPA-SC
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered DMPA-SC
Trial: 30894394
Drug: Provider-administered DMPA-SC
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-administered DMPA-SC
Trial: 28241271
Drug: Pill bottle
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill bottle strip with toggles
Trial: 20804848
Drug: Small sips
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small sips (5 mL)
Trial: 20804848
Drug: Large sips
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large sips (20 mL)
Trial: 18577289
Drug: Levodopa administration
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa administration (on condition)
Trial: 18577289
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug administration (off condition)
Trial: 14604194
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (1.4 g natural protein/kg target weight/day and 35 kcal/kg target weight/day)
Trial: 14604194
Drug: Calcium caseinate
RxNorm normalized name: calcium caseinate
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium caseinate (0.7 g calcium caseinate plus 0.7 g natural protein diet/kg target weight/day and 35 kcal/kg target weight/day)